Table 2.
Assessment of the microorganisms around CBP implants and antagonist natural teeth and implants.
Implants (n: 40) | Min–Max | Mean (SD) | % (+ Cases/40) |
CR | 8 (3) | ||
EC | 5 (2) | ||
FN | 3 (1) | ||
PM | 0 (0) | ||
PN | 25 (10) | ||
SA | 0 (0) | ||
SM | 0 (0) | ||
SE | 0 (0) | ||
CA | 0 (0) | ||
AA | 0.00–49.000 | 2.550 (9.722) | 2 (5) |
PG | 0.00–67,950.000 | 3002.900 (11,826.386) | 7 (18) |
PI | 0.00–2770.000 | 108.450 (483.836) | 3 (8) |
TF | 0.00–164,573.000 | 7001.180 (27,000.457) | 15 (38) |
TD | 0.00–4642.000 | 267.200 (884.403) | 11 (28) |
“Group 2” tot. | 0.00–40,946.200 | 2076.455 (7276.455) | 17 (43) |
Antagonist Natural Teeth (n: 40) | Min–Max | Mean (SD) | % (+ Cases/40) |
CR | 5 (2) | ||
EC | 15 (6) | ||
FN | 6 (2) | ||
PM | 3 (1) | ||
PN | 20 (8) | ||
SA | 0 (0) | ||
SM | 0 (0) | ||
SE | 0 (0) | ||
CA | 0 (0) | ||
AA | 0.00–69.000 | 3.630 (13.237) | 2 (5) |
PG | 0.00–75,986.000 | 4800.630 (15,165.136) | 10 (25) |
PI | 0.00–884.000 | 45.930 (155.593) | 7 (18) |
TF | 0.00–590,869.000 | 19,680.560 (94,548.644) | 22 (56) |
TD | 0.00–18,637.000 | 707.550 (3003.893) | 10 (25) |
“Group 2” tot. | 0.00–123,228.600 | 4949.255 (19,674.790) | 22 (55) |
Implants (n: 14) | Min–Max | Mean (SD) | % (Positive Cases/14) |
CR | 0 (0) | ||
EC | 0 (0) | ||
FN | 0 (0) | ||
PM | 0 (0) | ||
PN | 1 (7) | ||
SA | 0 (0) | ||
SM | 0 (0) | ||
SE | 0 (0) | ||
CA | 0 (0) | ||
AA | 0.000–4.000 | 0.290 (1.069) | 0 (0) |
PG | 0.000–24,942.000 | 2567.430 (7075.764) | 2 (14) |
PI | 0.000–548.000 | 73.570 (155.740) | 4 (29) |
TF | 0.000–5114.000 | 648.290 (1353.070) | 7 (50) |
TD | 0.000–5735.000 | 588.570 (1530.708) | 7 (50) |
“Group 2” tot. | 0.000–5838.200 | 775.629 (1561.634) | 7 (50) |
Mean (SD) and the percentage of positive cases. A microbiological sample was considered as a “weak negative” when up to 19 bacterial copies/μL were detected, while “weak positive” when the copies/μL were above this threshold; Min: minimum value; Max: maximum value; SD: standard deviation.